CRISPR-Cas systems, derived from bacterial adaptive immunity, have revolutionized genetic engineering.  This technology leverages a guide RNA (gRNA) molecule, programmed to target a specific DNA sequence, complexed with the Cas nuclease, typically Cas9.  The gRNA directs Cas9 to the target locus, where its endonuclease activity creates a double-strand break (DSB).  Cellular DNA repair mechanisms, namely non-homologous end joining (NHEJ) and homology-directed repair (HDR), then process the DSB.  NHEJ often introduces insertions or deletions, causing gene disruption, while HDR allows precise gene editing via the introduction of a donor DNA template.  This versatility allows for targeted gene knockout, gene insertion, and base editing, expanding the applications of genetic engineering.  Despite its precision, off-target effects remain a concern, requiring careful gRNA design and validation.  Ongoing research focuses on improving specificity, expanding targeting capabilities, and developing novel CRISPR-based tools for therapeutic applications, including gene therapy and disease modeling.